Edwards Lifesciences sees FY18 adjusted EPS $4.10-$4.30, consensus $4.15
Sees FY18 global sales of $3.5B-$3.9B, consensus $3.71B. "As we come to the end of 2017, our performance and accomplishments this year significantly exceeded our expectations, and we expect 2018 to be another strong year for Edwards Lifesciences. Our global growth is being driven by our transcatheter aortic valve therapies, and continued advancement in each of our market-leading product lines. In 2018, we are projecting strong financial results while we continue to invest aggressively to provide breakthrough therapies for patients in need. During the year, we expect to achieve a number of meaningful clinical milestones that will serve as indicators of our progress in advancing multiple transcatheter mitral and tricuspid programs," said Michael Mussallem, Edwards Lifesciences chairman and CEO.